Introduction
Routine antenatal serological screening has been practised throughout the United Kingdom and worldwide for about 30 years.' Originally introduced to detect pregnancies at risk of haemolytic disease of the newborn (HDN) due to Rh anti-D antibodies, its continued use has led to an increasing realisation of the clinical importance of other red cell antibodies in the pathogenesis of HDN.
Three factors are essential in the pathogenesis of HDN: maternal red cell antibodies must cross the placenta, the fetal red cells must possess the appropriate red cell antigen against which the antibodies are directed, and the antibodies must be capable of causing immune destruction. The clinically relevant antibodies are, therefore, virtually always IgG and reactive at 37°C. About 2-5% of women will have such antibodies as a result of transfusion, pregnancy, or both; it is, therefore, important for the pregnant patient, the fetus, and their clinical advisors that appropriate antenatal screening tests are performed. There is no value in identifying group 0 mothers with high titres of anti-A or anti-B. Antenatal testing of these antibodies has been shown to have no value in predicting the incidence of ABO HDN. The lytic potential of maternal IgG anti-A and anti-B is very variable, and frequently the IgG subclass which predominates in these group 0 patients is IgG2, a subclass which does not induce red cell destruction. A further reason for being unable to predict the incidence of ABO HDN is the very variable density of A and B antigen on fetal red cells. 4 There is an increased incidence and an increased severity of ABO HDN in certain populations: Arabs, Negroes, South-East Asians, and Latin-Americans, but again there is little predictive value from serological monitoring. However, it is essential that early postnatal diagnosis and management should be undertaken in children born to women from these particular ethnic groups.
There Antibody screening tests using enzyme treated red cells are not required for routine antenatal screening. Their use is associated with an increased antibody detection rate, but many of these reactions are false positives. Antibodies are also detected which are not associated with HDN because they are not IgG, or because they react only in the presence of enzyme modified red cells. Laboratories that have access to samples taken only at an early stage of pregnancy for their RhD positive patients will often use this technique in the hope that its increased sensitivity will lead to early detection of antibodies that will develop clinical significance during pregnancy. Early detection of these antibodies enables the clinician to be alerted to the need for further sampling later in pregnancy for these patients.
ANTIBODIES OF CLINICAL SIGNIFICANCE
The antibodies most often implicated in causing severe to moderate HDN are anti-D, -c, and -Kell, but other antibodies are also recognised as a cause of HDN (table 2) .There are numerous reports of IAT reacting antibodies being implicated in HDN of moderate severity, and all women found to have an IAT reacting red cell antibody in early pregnancy should be regarded as requiring further investigation. The majority will merely require repeat testing later in pregnancy (28 to 36 weeks); after delivery the baby should be tested for HDN and his/her red cells typed for the implicated antigen. Women with a previous history of children with HDN in association with the same red cell antibody should be managed more actively in line with the management outlined below for anti-D, -c, -Kell.
Women with anti-D, -c, -Kell antibodies (and others with a previous clinical history of HDN) Routine screening of pregnant women for atypical red cell antibodies is also an essential part of antenatal care. The decline in the incidence of anti-D antibodies has led to a decreased incidence of HDN but the cases that occur are associated with a greater variety of antibodies. These require careful laboratory investigation both for their identification and assessment of clinical significance. Few hospitals have wide experience in handling the variety of cases which may occur and it is, therefore, important that, not only is there very close cooperation between laboratory staff, haematologists, obstetricians, and midwives within a single hospital setting but also with reference laboratories and centres capable of performing fetal transfusions. Modern laboratory techniques, employing cellular assays and amniocyte DNA fetal blood typing, coupled with skilled ultrasound assessment of early fetal hydrops, enables obstetricians to help their patients to make informed decisions before invasive procedures such as fetal blood sampling are undertaken.
A multidisciplinary approach involving careful clinical assessment, evaluation of previous history, laboratory testing, and, where necessary, non-invasive and invasive assessment of fetal wellbeing, sometimes coupled with intrauterine transfusion, is the only way ofproviding effective management of pregnancies complicated by red cell antibodies. Maternal and fetal wellbeing must be assured in these cases and careful informed consideration of the likely significance of any red cell antibodies detected for both HDN and transfusion support will help to ensure the optimal outcome for the mother and her child.
